In addition, ovarian cancers with defective BRCA1/2 genes are especially susceptible to agents that induce DNA double-strand breaks (DSBs) [58] and DNA interstrand cross-links, such as platinum compounds (e.g., cisplatin and carboplatin) and polymerase (PARP) inhibitors (e.g., Olaparib, Iniparib and Veliparib) [39,59]. Here, BRCA1 is linked to ovarian cancer.